Author Archives: collabrx

CollabRx Targeted Therapy Finder noted by FDA (Genome Web)

An article appearing in the Nov. 2, 2011 issue of Genome Web highlights the CollabRx Targeted Therapy Finders in the context of a discussion about the complexities of pre-screening regarding clinical trials for personalized (targeted) therapies. Thomas Gwise, deputy director of the FDA’s biometrics division, is quoted as saying that online tools such as the […]

Targeted Therapies Improve Prognosis for Lung Cancer Patients

February, 2012 — CollabRx’s Lung Cancer Targeted Therapy Finder and Dr. Ravi Salga, chief editor and advisor for the Lung Cancer Targeted Therapy Finder, are featured in an article published by the University of Chicago School of Medicine as part of their Comprehensive Cancer Center’s lung cancer program. Read More at University of Chicago  

Lung Cancer Molecular Disease Model Published in PLoS ONE

A team including leading lung cancer researchers, and CollabRx scientists, has just published a novel Lung Cancer Molecular Disease Model in PLoS ONE, a leading peer-reviewed open source journal. (click here to read the published paper online). This is the model that underlies the CollabRx Lung Cancer Targeted Therapy Finder App.    

Cancer Commons Researchers Publish Molecular Disease Model for Lung Cancer

PALO ALTO, Calif.–(BUSINESS WIRE)–Cancer Commons, an open‐science initiative to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model (MDM) for lung cancer. The paper, by Lisandra West, Ravi Salgia, and others will appear in the February 21st issue of PLoS ONE. The lung cancer MDM classifies the disease into subtypes based […]

CollabRx apps discussed in the British Journal of Healthcare Computing

The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy Finder […]

CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology

Publication Establishes Standard Framework to Guide Therapy Selection for Targeted Therapies in Cancer SanFrancisco,CA –November5,2014– CollabRx, Inc. (NASDAQ: CLRX), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 The publication […]

CollabRx Announces Pricing Of Public Offering Of Approximately $4,800,000 Of Common Stock And Warrants

SAN FRANCISCO, Feb. 19, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX) today announced the pricing of an underwritten public offering of 3,840,000 shares of its common stock and warrants to purchase up to an aggregate of 3,840,000 shares of its common stock at an offering price of $1.25 per common share and $0.0001 per warrant. […]

CollabRx Announces Pricing Of Public Offering Of Approximately $3,000,000 Of Common Stock

SAN FRANCISCO, Feb. 25, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX) today announced the pricing of an underwritten public offering of 2,362,205 shares of its common stock at a price to the public of $1.27 per share. Gross proceeds to CollabRx from this offering are approximately $3,000,000 before deducting underwriting discounts and commissions and other […]

CollabRx and Medytox Solutions Sign Definitive Merger Agreement

Combination Will Create New Generation Healthcare Company  SAN FRANCISCO, CA and WEST PALM BEACH, FL – April 16, 2015 — CollabRx, Inc. (NASDAQ:CLRX) (“CollabRx”) and Medytox Solutions, Inc. (OTCQB: MMMS) (“Medytox”) today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from […]

CollabRx Receives Notice from Nasdaq on Change of Control

Company Reconfirms Intent to Remain on Nasdaq San Francisco, CA – April 29, 2015 – CollabRx, Inc. (NASDAQ: CLRX) (“CollabRx” or “the Company”), today announced that it had received notice from The NASDAQ Stock Market LLC (“Nasdaq”) that the Company’s proposed transaction with Medytox Solutions, Inc. (OTCQB: MMMS) (“Medytox”) when completed would constitute a business combination […]